(Q34993877)

5 August 2017

1 reference

title

Clinical relevance of mechanisms of antifungal drug resistance in yeasts (English)

1 reference

antifungal drug resistance

5 August 2017

main subject

1 reference

1

Dominique Sanglard

1 reference

5 August 2017

publication date

1 November 2002

1 reference

Infectious Diseases and Clinical Microbiology

5 August 2017

published in

1 reference

5 August 2017

volume

20

1 reference

5 August 2017

issue

9

1 reference

5 August 2017

page(s)

462-9; quiz 470, 479

1 reference

Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Te

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2802%2972842-5

7 January 2021

Detection of amphotericin B-resistant Candida isolates in a broth-based system

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2802%2972842-5

7 January 2021

Improved detection of amphotericin B-resistant isolates of Candida lusitaniae by Etest

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2802%2972842-5

7 January 2021

Strain delineation and antifungal susceptibilities of epidemiologically related and unrelated isolates of Candida lusitaniae.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2802%2972842-5

7 January 2021

Trichosporon beigelii, an emerging pathogen resistant to amphotericin B

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2802%2972842-5

7 January 2021

Isolation and characterization of fluconazole- and amphotericin B-resistant Candida albicans from blood of two patients with leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2802%2972842-5

7 January 2021

Resistance to amphotericin B associated with defective sterol delta 8-->7 isomerase in a Cryptococcus neoformans strain from an AIDS patient

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2802%2972842-5

7 January 2021

Incidence of polyene-resistant yeasts recovered from clinical specimens

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2802%2972842-5

7 January 2021

Amphotericin B-induced oxidative damage and killing of Candida albicans

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2802%2972842-5

7 January 2021

Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2802%2972842-5

7 January 2021

A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2802%2972842-5

7 January 2021

Clinical, cellular, and molecular factors that contribute to antifungal drug resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2802%2972842-5

7 January 2021

Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2802%2972842-5

7 January 2021

Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter gene.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2802%2972842-5

7 January 2021

Rapid, transient fluconazole resistance in Candida albicans is associated with increased mRNA levels of CDR.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2802%2972842-5

7 January 2021

Inducible azole resistance associated with a heterogeneous phenotype in Candida albicans.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2802%2972842-5

7 January 2021

Role of ATP-binding-cassette transporter genes in high-frequency acquisition of resistance to azole antifungals in Candida glabrata.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2802%2972842-5

7 January 2021

Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2802%2972842-5

7 January 2021

Mutation in cytochrome P-450-dependent 14 alpha-demethylase results in decreased affinity for azole antifungals.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2802%2972842-5

7 January 2021

Resistant P45051A1 activity in azole antifungal tolerant Cryptococcus neoformans from AIDS patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2802%2972842-5

7 January 2021

Molecular biological characterization of an azole-resistant Candida glabrata isolate

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2802%2972842-5

7 January 2021

Genomic profiling of the response of Candida albicans to itraconazole treatment using a DNA microarray

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2802%2972842-5

7 January 2021

Cloning, sequencing, expression and allelic sequence diversity of ERG3 (C-5 sterol desaturase gene) in Candida albicans

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2802%2972842-5

7 January 2021

Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2802%2972842-5

7 January 2021

The ATP binding cassette transporter gene CgCDR1 from Candida glabrata is involved in the resistance of clinical isolates to azole antifungal agents.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2802%2972842-5

7 January 2021

Investigation of multidrug efflux pumps in relation to fluconazole resistance in Candida albicans biofilms

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2802%2972842-5

7 January 2021

Declining rates of oropharyngeal candidiasis and carriage of Candida albicans associated with trends toward reduced rates of carriage of fluconazole-resistant C. albicans in human immunodeficiency virus-infected patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2802%2972842-5

7 January 2021

The evolution of Candida species and fluconazole susceptibility among oral and vaginal isolates recovered from human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2802%2972842-5

7 January 2021

Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2802%2972842-5

7 January 2021

Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates in the United States: 1992 to 1994 and 1996 to 1998.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2802%2972842-5

7 January 2021

Trends in species distribution and susceptibility to fluconazole among blood stream isolates of Candida species in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2802%2972842-5

7 January 2021

In vitro susceptibility of environmental Cryptococcus neoformans variety neoformans isolates from Turkey to six antifungal agents, including SCH56592 and voriconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2802%2972842-5

7 January 2021

In vitro activities of ravuconazole (BMS-207147) against 541 clinical isolates of Cryptococcus neoformans

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2802%2972842-5

7 January 2021

In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872)

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2802%2972842-5

7 January 2021

In vitro antifungal activity of FK463, a new water-soluble echinocandin-like lipopeptide

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2802%2972842-5

7 January 2021

In-vitro activity of voriconazole (UK-109,496), LY303366 and other antifungal agents against oral Candida spp. isolates from HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2802%2972842-5

7 January 2021

In vitro susceptibilities of clinical yeast isolates to a new echinocandin derivative, LY303366, and other antifungal agents.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2802%2972842-5

7 January 2021

In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2802%2972842-5

7 January 2021

Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2802%2972842-5

7 January 2021

10.1016/S0213-005X(02)72842-5

Identifiers

DOI

1 reference

release_gvr6kv6k4ff4tk7gz6ejcjxgj4

5 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/gvr6kv6k4ff4tk7gz6ejcjxgj4

24 November 2022

mapped directly with Wikidata item

1 reference